A critical care team is evaluating a 68-year-old patient during morning rounds. The patient was admitted to the intensive care unit three days ago for severe community-acquired pneumonia and septic shock, which required endotracheal intubation and vasopressor support. The patient has a medical history of chronic obstructive pulmonary disease (COPD) and hypertension.
Over the past 24 hours, the patient has been afebrile, and vasopressors were successfully discontinued. The patient remains sedated on volume-controlled mechanical ventilation.
Blood and endotracheal aspirate cultures obtained upon admission are now finalized and demonstrate heavy growth of Streptococcus pneumoniae, which is susceptible to penicillin, ceftriaxone, and azithromycin. The patient is currently receiving empiric intravenous vancomycin, cefepime, and levofloxacin.
Physical examination reveals a jugular venous pressure of 5 cm . Lung auscultation demonstrates bilateral expiratory wheezing with scattered rhonchi, but no crackles. Heart sounds are regular without or gallops. There is no peripheral edema.
| Test | Value |
|---|---|
| Sodium | 140 mEq/L |
| Potassium | 4.1 mEq/L |
| Chloride | 105 mEq/L |
| Bicarbonate | 18 mEq/L |
Arterial blood gas on current ventilator settings:
* pH: 7.33
* : 35 mmHg
* : 72 mmHg
Based on the patient's current clinical status and laboratory findings, which of the following are appropriate components of this patient's management plan today? (Select all that apply)
- Transition the antimicrobial regimen to intravenous ceftriaxone monotherapyAnswer
- Maintain the current minute ventilation as the arterial blood gas reflects an appropriately compensated metabolic acidosisAnswer
- CAdminister intravenous furosemide to manage acute decompensated heart failure as the primary cause of bilateral wheezing
- DIncrease the ventilator respiratory rate to treat an underlying primary respiratory acidosis
- EContinue the empiric regimen of vancomycin, cefepime, and levofloxacin to ensure adequate coverage of potential hospital-acquired pathogens